secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001728117-23-000107
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio Q2 net loss $42.5M; raises $212M in July private placement
-----------------------------------------------------------------------

- Net loss $42.5M ($0.45/share) vs $56.5M ($0.74) in Q2 2022; R&D expenses decreased to $36.3M.
- Cash, equivalents & marketable securities $162.1M as of June 30; pro forma for July placement total $374M.
- Phase 3 PROSERA study of seralutinib in PAH expected to start in Q3 2023; primary endpoint 6MWD at week 24.
- Additional TORREY open-label extension data expected in Q4 2023 or Q1 2024.
- July private placement raised ~$212M gross from sale of shares and warrants to institutional investors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000107/0001728117-23-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000107/goss-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001728117-23-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer